These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 683547)

  • 21. [Proinsulin and a-component antibodies in diabetics treated with monocomponent and conventional insulin].
    Gamba S; Barbero PL; Bollati C; Castellazzi R; D'Adda A; Bruni B
    Minerva Dietol Gastroenterol; 1979; 25(3):309-14. PubMed ID: 400003
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experiences with monocomponent insulin].
    Fagerberg SE; Gamstedt A
    Lakartidningen; 1976 Nov; 73(47):4097-9. PubMed ID: 994601
    [No Abstract]   [Full Text] [Related]  

  • 23. [Are des-Phe-insulin-containing insulin combinations preferable to regular trade preparations?].
    Sachse G; Federlin K
    Med Klin; 1981 May; 76(11):319-23. PubMed ID: 7017364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of injection techniques for soluble and protamine zinc insulins in diabetes mellitus.
    Harrower AD; Duncan LJ; Clarke BF
    Practitioner; 1975 Feb; 214(1280):228-31. PubMed ID: 1144249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical aspects of monocomponent insulins in the treatment of diabetes.
    Vinik AI; Joffe BI; Seftel HC; Distiller LA; Jackson WP
    S Afr Med J; 1976 Apr; 50(15):587-91. PubMed ID: 1265555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serum levels of insulin-binding antibodies treated with monocomponent insulin].
    Czyzyk A; Lawecki J; Rogala H; Miedzińska E; Popik-Hankiewicz A
    Pol Tyg Lek; 1974 Feb; 29(8):301-4. PubMed ID: 4856084
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative trials with monocomponent (MC) and monospecies (MS) pork insulins in the treatment of diabetes mellitus. Influence on antibody levels, on insulin requirement and on some complications.
    Andreani D; Iavicoli M; Tamburrano G; Menzinger G; Maltarello C
    Horm Metab Res; 1974 Nov; 6(6):447-54. PubMed ID: 4476720
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pathogenesis of diabetic microangiopathy. Fluoroangioretinal observations during monocomponent insulin therapy].
    Anselmetti G; Antoniotti V; Barbero PL; Castellazzi R; Gamba S; Bruni B
    Ann Osp Maria Vittoria Torino; 1978; 21(1-6):47-68. PubMed ID: 756200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Are there problems in changing diabetic patients from animal to human insulin?].
    Fankhauser S; von Rohr E
    Ther Umsch; 1990 Jan; 47(1):41-8. PubMed ID: 2408181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of high-purity insulins in the treatment of patients with diabetes mellitus].
    Spesivtseva VG; Pokryshkin VI; Belokrinitskiĭ ; Koroleva TV; Mamaeva GG
    Ter Arkh; 1987; 59(11):22-6. PubMed ID: 3327181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characterisation of activity of a biphasic monocomponent insulin (author's transl)].
    Neubauer M; Althoff PH; Schnabel O; Genrich V; Schöffling K
    Dtsch Med Wochenschr; 1979 Mar; 104(11):384-90. PubMed ID: 421667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HLA typing and insulin antibody production in insulin-dependent diabetics].
    Bruni B; Barolo P; Gadaleta G; Gamba Ansaldi S; Grassi G; Zerbinati A; Molinatti M; Salvetti E
    Ann Osp Maria Vittoria Torino; 1984; 27(7-12):185-213. PubMed ID: 6443704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment.
    Bruni B; Gamba S; Regis G; Turco GL
    Diabetologia; 1978 Mar; 14(3):165-9. PubMed ID: 566232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Proceedings: 2 years of experiences with monocomponent insulin in diabetic patients].
    Fankhauser S; Michl J; Morell B
    Helv Med Acta; 1974 May; 37(5-6):365-6. PubMed ID: 4605883
    [No Abstract]   [Full Text] [Related]  

  • 36. [Experiences with monocomponent (MC) insulin in the treatment of juvenile diabetes].
    Aronson S; Engleson G
    Lakartidningen; 1976 Nov; 73(46):3982-4. PubMed ID: 790057
    [No Abstract]   [Full Text] [Related]  

  • 37. [New insulins in diabetes therapy].
    Morell B
    Schweiz Med Wochenschr; 1979 Mar; 109(10):362-5. PubMed ID: 570723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.
    Anderson OO
    Acta Endocrinol (Copenh); 1975 Apr; 78(4):723-35. PubMed ID: 1173962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical examination of diabetic patients treated with monocomponent insulin manufactured by MP Polfa].
    Orłowska-Kunikowska E; Horoszek-Maziarz S; Loss-Fisior R; Semetkowska-Jurkiewicz E; Dominiak K; Wójcikowski C
    Pol Tyg Lek; 1989 May 22-29; 44(21-22):503-6. PubMed ID: 2702341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.